Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Study Information
Alliance Study ID: CALGB 10503
NCT Study ID (ClinicalTrials.gov): NCT00416598
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: William Blum
Status: COMPLETED
Study Description
This phase II trial is studying the side effects and how well decitabine works when given as maintenance therapy after standard therapy in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin, etoposide, busulfan, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving decitabine as maintenance therapy after standard therapy may keep cancer cells from coming back.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information